Fig. 2: CT imaging of the patient under treatment.

a, b Follow-up CT scan from September 2017 shows a partial response to imatinib, with reduced size of periesophageal and hepatic lesions (red arrows). c By February 2018, CT imaging reveals disease progression, with new intra-abdominal lesions, including an 8 cm perigastric mass with central necrosis (red arrow). d Following imatinib dose escalation, further progression is observed, including enlargement of the perigastric mass. e Imaging obtained at the late-stage of disease showing a large tumor mass occupying most of the abdominal cavity.